Leinco Technologies

Anti-Human IL-6 (Sarilumab) Dylight® 488

Product Code:
 
LEI-LT1711
Product Group:
 
Primary Antibodies
Host Type:
 
Human
Antibody Isotype:
 
Human IgG1κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
Hu137
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Flow Cytometry
  • Functional Study
  • Immunohistochemistry (IHC)
Shipping:
 
2-8°C
Storage:
 
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-LT1711-100ug100 ug£352.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
IL-6R is ubiquitously expressed.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 488
Format:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Long Description:
IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6?mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.
NCBI Gene:
3569
Target:
IL-6

References

1. Kevzara (sarilumab) injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; Bridgewater, NJ: sanofi-aventis U.S.; May 2017. 2. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. 3. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020.